JNM Impact Factor Rises Again

SNMMI and editors of *The Journal of Nuclear Medicine* (*JNM*) announced on June 28 that the publication had achieved the highest impact factor in its history, ranking fourth among all medical imaging journals, according to new data released in the *2021 Journal Citation Reports*. "This continued rise in visibility emphasizes not only the high quality of the journal but also the rise in importance of nuclear medicine as a whole," said *JNM* editor-in-chief Johannes Czernin, MD. "Revolutionary advances in nuclear medicine research are resulting in revolutionary care for patients."

JNM's impact factor increased more than 10% over last year, from 10.057 (2020) to 11.082 (2021). With 35,215 total citations, the journal was fourth in impact factor and third in Journal Citation Indicator among 200 journals in the medical imaging category. *JNM*'s total citations increased by 7%, and its 5-year impact factor increased almost 15%. Among nuclear medicine journals, *JNM* continues to have the highest impact factor, total citations, 5-year impact factor, Eigenfactor and normalized Eigenfactor scores, and article influence score.

"This is a tribute to the contributions of diverse scientists from all areas of the field, from advances in imaging instrumentation to important aspects of theranostic and therapeutic approaches," said Czernin. *JNM* has highlighted some of those advances in recent supplements focused on personalized dosimetry for cancer therapy, nuclear endocrinology, and molecular imaging of neurodegeneration.

The impact factor is a quantitative measure of the frequency with which an article in a journal is cited. It is used as a measure of the overall influence of a journal within scientific, professional, and academic communities. "I am grateful for the support of SNMMI and its Publications Committee, the valuable contributions of our staff, the vital input from our editorial board and reviewers, and the dedication and expertise of the team of associate editors whose work made this success possible," said Czernin.

SNMMI

(*Continued from page 17N*)

provide Current Good Manufacturing Practice–grade ^{225}Ac.

NorthStar Medical Radioisotopes
Curie Therapeutics, Inc.

Thomas J. Maloney, 1929–2022

Thomas J. Maloney, of Friendswood, TX, whose involvement with nuclear medicine and the radiopharmaceutical industry spanned more than half a century, died on March 29 at the age of 92. He was well known in nuclear medicine as the founder and owner of Iso-Tex Diagnostics, Inc., a radiopharmaceutical manufacturing firm, and Tel-Test, Inc., a provider of molecular reagents. Both companies were in Friendswood.

Maloney's long career began with completion of a 4-y apprentice program at General Electric (GE) as a tool and die maker, from which he transferred into the GE top-secret atomic submarine and Microgun research programs. He also trained in mechanical engineering at Union College (Schenectady, NY). He enlisted as a Graduate Officer candidate in the U.S. Army, where he served as an Expert Infantry Officer, Paratrooper 101st Airborne Division, Company Commander, Regimental Law Officer, and a commissioned First Lieutenant, Infantry. He later worked at Union Carbide as a mechanical engineer supervisor and a senior licensed atomic energy reactor operator in Tuxedo Park, NY, producing radiochemicals. He went on to become president of Cambridge Nuclear and later of Bio Nuclear (Houston, TX), before founding Iso-Tex and Tel-Test in 1975. His long career in the radiopharmaceutical industry included multiple patents, New Drug Applications, and Investigational New Drug applications.

Houston Chronicle